Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | POLB | P06746 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.74 |
| ▸ | RECQL | P46063 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | EIF4E | P06730 | 1/20 | 0.74 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892304 | 1.00 | APEX1 (0.79) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL29701307 | 1.00 | APEX1 (0.79) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL29974484 | 0.91 | APEX1 (0.77) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL12177362 | 0.90 | MEN1 (0.69) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL23145046 | 0.89 | STAT3 (0.76) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL18301010 | 0.89 | STAT3 (0.76) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL46211 | 0.89 | STAT3 (0.76) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL3897857 | 0.89 | APEX1 (1.00) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL8594643 | 0.89 | MEN1 (0.71) | APEX1MEN1KMT2APOLBMAPT | |
| SCHEMBL3897850 | 0.89 | APEX1 (1.00) | APEX1MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| EP-1802297-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | APEX1 1572/4885MEN1 1562/4885KMT2A 901/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | APEX1 888/4885MEN1 2869/4885KMT2A 1020/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | APEX1 4461/4885MEN1 2930/4885KMT2A 901/4885 |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | PTPRS, PTPRO, PTPN5 | APEX1 3092/4885MEN1 2038/4885KMT2A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.